Overview

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.

Status:
Recruiting
Trial end date:
2026-05-08
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AstraZeneca